{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIc+Melanoma&page=7",
    "query": {
      "condition": "Stage IIIc Melanoma",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 152,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIc+Melanoma&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIc+Melanoma&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T20:00:16.393Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04375527",
      "title": "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC V8",
        "Clinical Stage IV Cutaneous Melanoma AJCC V8",
        "Locally Advanced Cutaneous Melanoma",
        "Metastatic Cutaneous Melanoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC V8",
        "Unresectable Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-12-03",
      "completion_date": "2024-11-22",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375527"
    },
    {
      "nct_id": "NCT02419495",
      "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Fallopian Tube Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Renal Cell Carcinoma",
        "Ovarian Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Primary Peritoneal Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Melanoma",
        "Unresectable Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2015-06-26",
      "completion_date": "2024-09-16",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 5,
      "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "League City",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419495"
    },
    {
      "nct_id": "NCT00089362",
      "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Breast Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Gastric Cancer",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Melanoma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Colon Cancer",
        "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Gastric Cancer",
        "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Lymphoepithelioma of the Oropharynx",
        "Stage III Melanoma",
        "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Gastric Cancer",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Melanoma",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "alvespimycin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-10",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089362"
    },
    {
      "nct_id": "NCT01950390",
      "title": "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2014-01-24",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 482,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 298 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01950390"
    },
    {
      "nct_id": "NCT03154190",
      "title": "Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Brain Glioblastoma",
        "Estrogen Receptor Negative",
        "Extensive Stage Small Cell Lung Carcinoma",
        "Head and Neck Carcinoma",
        "HER2/Neu Negative",
        "Hormone-Resistant Prostate Cancer",
        "Limited Stage Small Cell Lung Carcinoma",
        "Myelodysplastic Syndrome",
        "Progesterone Receptor Negative",
        "Progressive Disease",
        "Recurrent Carcinoma",
        "Stage II Pancreatic Cancer",
        "Stage II Rectal Cancer",
        "Stage IIA Pancreatic Cancer",
        "Stage IIA Rectal Cancer",
        "Stage IIB Pancreatic Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIC Rectal Cancer",
        "Stage III Colon Cancer",
        "Stage III Esophageal Cancer",
        "Stage III Gastric Cancer",
        "Stage III Non-Small Cell Lung Cancer",
        "Stage III Ovarian Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Skin Melanoma",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Esophageal Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Esophageal Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Esophageal Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IIIC Skin Melanoma",
        "Stage IV Bladder Cancer",
        "Stage IV Bone Sarcoma",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IV Soft Tissue Sarcoma",
        "Stage IVA Bone Sarcoma",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Bone Sarcoma",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2017-08-08",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 1,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154190"
    },
    {
      "nct_id": "NCT00289016",
      "title": "A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioVex Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-12",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2015-12-18",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Robbinsdale",
          "state": "Minnesota"
        },
        {
          "city": "Montclair",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00289016"
    },
    {
      "nct_id": "NCT01902173",
      "title": "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        },
        {
          "name": "Uprosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2013-10-08",
      "completion_date": "2023-12-23",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01902173"
    },
    {
      "nct_id": "NCT04771520",
      "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Primary Malignant Central Nervous System Neoplasm",
        "Locally Advanced Sarcoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Primary Malignant Central Nervous System Neoplasm",
        "Metastatic Sarcoma",
        "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avapritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-01-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771520"
    },
    {
      "nct_id": "NCT01368276",
      "title": "An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BioVex Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2010-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-18",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Robbinsdale",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01368276"
    },
    {
      "nct_id": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Intraocular Melanoma",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        },
        {
          "name": "131I-3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 78,
      "start_date": "2006-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-21T20:00:16.393Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445965"
    }
  ]
}